Surlorian for RYR1 muscle weakness: strength and safety study
Part of Bones, joints & muscles clinical trials.
This trial tests whether a new drug called Surlorian can improve muscle strength in adults with a rare genetic muscle condition (RYR1-related myopathy). You'd receive either the drug or a placebo and be monitored for safety and changes in muscle function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed genetic diagnosis of RYR1-related myopathy with an autosomal dominant mutation
- You experience weakness in upper arm, shoulder, or hip muscles (proximal muscles)
- You can walk 10 meters, with or without a cane
- You are willing to use effective birth control if you can have children, or you cannot have children
- You do not have severe lung disease, heart disease, or other neuromuscular conditions besides RYR1-myopathy
- You are not currently taking certain medications (like statins, acid reflux drugs, or specific heart/liver medications) or can stop them before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with RYR1-related disorders over time to learn how the condition progresses. It may help researchers plan future treatments.
This trial is testing a new drug called SRP-1003 for people with myotonic dystrophy type 1 (DM1) who developed symptoms after age 12. The goal is to see if it can reduce muscle problems like myotonia (difficulty relaxing muscles) and improve daily function.
This study looks at people with RYR1-related conditions like muscle weakness or malignant hyperthermia. The goal is to learn more about these conditions and how common they are.
This trial tests an experimental drug called MRG-001 for people with amyotrophic lateral sclerosis (ALS). It aims to see if the drug can help slow the progression of the disease.
This trial is testing an investigational drug, SRP-1001, to see if it helps people with facioscapulohumeral muscular dystrophy type 1 (FSHD1), a condition that causes muscle weakness. The study will check if the drug is safe and if it can slow down the loss of muscle function.
This trial tests surovatamig, a new experimental treatment, to see if it's safe and how the body processes it in adults with moderate-to-severe rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). It may be an option if you've tried other biologic or targeted therapies without success.
Hear when a new Autosomal Dominant RYR1-Related Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.